Today's news.
Attention Business Editors:
INFLAZYME PHARMACEUTICALS APPOINTS VICE-PRESIDENT FOR PRE-CLINICAL AND REGULATORY
AFFAIRS
VANCOUVER, Oct. 29 /CNW/ - Inflazyme Pharmaceuticals Ltd. (OTC-BB:IZYPF,
VSE:IZP) today announced the appointment of Dr. John Blasecki as
Vice-President of Pre-Clinical and Regulatory Affairs. He will manage liaisons
between Inflazyme's scientists and contract research organizations (CROs) and
the Food and Drug Administration (FDA).
Dr. Blasecki will focus immediately on Apanol, Inflazyme's orally active
anti-asthma drug. He will work closely with Scirex, a CRO, to prepare and
submit the drug for FDA approved clinical trials. Noting that steroids, with
harmful side effects, have dominated asthma treatment for the past 30 years,
Inflazyme's CEO Dr. Hassan Salari stated, ``It is critical for us to speed up
the clinical trials of Apanol, and having someone with the experience of Dr.
Blasecki leading its development will help to expedite its approval.''
Prior to joining Inflazyme, Dr. Blasecki spent more than 17 years in
several senior positions with Dupont and Merck-Dupont Pharmaceuticals. He
later served as Director of Preclinical Research and Development at Cytran,
Inc. where he also managed liaisons between internal scientists and the FDA on
the filing and approval of several drugs. He brings to Inflazyme a wealth of
experience and knowledge in drug development and in IND and NDA protocols.
``Inflazyme has a portfolio of very promising drug candidates which have
good potential for obtaining a share of the anti-inflammatory market, said Dr.
Blasecki. He added, ``This has influenced my decision to join at an early
stage of development and participate in building a highly successful, fully
integrated pharmaceutical company.''
Inflazyme is a bio-pharmaceutical company focused on the discovery and
development of therapeutic agents for diseases with a major inflammatory
component. lnflazyme's lead compound, Apanol, appears to possess unique
properties that may make it an orally effective agent for the treatment of
asthma. Other lead indications for Inflazyme's developing technologies include
allergy, arthritis and psoriasis. |
